Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial
Article content
First patient dosed with topical RLS-1496 in clinical trial will assess the safety and clinical effects of single and multiple doses to treat adults with mild to moderate and stable plaque psoriasis, skin aging, and additional inflammatory diseases, including atopic dermatitis, vitiligo, rosacea, alopecia areata, and scleroderma 1
Article content
Article content
RLS-1496 – a first-in-class disease-altering GPX4 modulator selectively targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process 2 – is the first GPX4 modulator to enter a human clinical trial, ahead of many leading biopharmaceutical companies evaluating the same target
Article content
RLS-1496 uses Rubedo's proprietary, AI-driven drug discovery platform ALEMBIC™, which identifies targets within pathologic senescent cells and develops selective cellular rejuvenation medicines for these targets
Article content
SAN FRANCISCO — Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the first patient has been dosed with lead drug candidate RLS-1496 in the company's single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial. The study marks the first time a GPX4 (glutathione peroxidase) modulator has entered Phase 1 clinical trial and is designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496 in male or female patients 18 years or older with mild to moderate and stable plaque psoriasis. These subjects' aging skin will also be treated and assessed to see if RLS-1496 can improve biomarkers of aging and reverse the skin age or biological clock. Based on the results of this study, the trial will potentially expand to additional inflammatory skin conditions and autoimmune disorders, including but not limited to atopic dermatitis, vitiligo, rosacea, alopecia areata, and scleroderma. 3 A systemic formulation of RLS-1496 is planned to enter Phase 1 clinical trials in 2026.
Article content
'We are excited to reach this important milestone not only for our lead candidate RLS-1496 but also for the advancement of longevity science,' said Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, FACMS. 'As the first company to treat patients with a GPX4 modulator targeting senescent cells in a data-rich Phase 1 clinical trial, we look forward to assessing its potential disease-altering effects on inflammatory skin conditions and skin aging, driving our pipeline forward in line with our goal of making a meaningful impact on age-related diseases and conditions, such as obesity and pain.'
Article content
Rubedo Chief Scientific Officer Marco Quarta, PhD, said, 'For the last decade, longevity scientists have been working to develop a compound ready for human trials that safely and effectively targets pathologic senescent cells. We are proud that our team developed RLS-1496 into a topical drug candidate in less than three years from initiation – two times faster than the industry average 1 via ALEMBIC™, our proprietary AI-driven drug discovery platform with SenTeCh™ chemistry technology. The other candidates in our pipeline are following similar expedited timelines, including systemic RLS-1496, which is aimed to begin Phase 1 clinical trials in 2026.'
Article content
The design of the clinical trial is to assess primary and secondary objectives of safety and clinical effects of single and multiple doses of topical RLS-1496, compared to vehicle (control), in patients with mild to moderate stable plaque psoriasis. A key secondary objective is to evaluate the effects of RLS-1496 on target psoriasis lesions using a common measure of psoriasis severity, the modified Investigator's Global Assessment (mIGA), to evaluate improvement. The trial will be conducted at a single center in The Netherlands with approximately 24 enrolled patients, starting with single dose application followed by a multidose protocol.
Article content
The design of the trial was developed with key insights provided by Rubedo's Clinical Advisory Board (CAB), which is led by Rubedo Chief Medical Officer and dermatologist Mary Spellman, MD. The CAB includes the following leading dermatologists who are both practicing clinicians and researchers, and are supporting Rubedo as strategic and scientific consultants and advisors:
Article content
Mark Lebwohl, MD, Professor & Chairman Emeritus of the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, NY
Ted Lain, MD, MBA, Executive Director & Principal Investigator, Austin Institute for Clinical Research; CMO, Sanova Dermatology, Austin, TX
Zoe Draelos, MD, Founder, Dermatology Consulting Services, High Point, NC
Chris Griffiths, OBE MD FRCP, Emeritus Professor of Dermatology, University of Manchester; Adjunct Professor of Dermatology, Kings College of London, London, England
Article content
Dr. Lebwohl said, 'As clinicians, we are excited about the potential use of RLS-1496 as a topical treatment for psoriasis, other chronic inflammatory skin conditions, and skin aging itself. As researchers, we are intrigued by RLS-1496 as a potential first-in-class GPX4 modulator that was designed to selectively target inflammaging pathologic senescent cells and surrounding tissues. This is a very important milestone in longevity science, and we are thrilled to be working with the Rubedo team to drive this science forward.'
Article content
Rubedo's lead candidate RLS-1496 is a potential first-in-class, disease-altering GPX4 modulator selectively targeting pathologic senescent 'zombie' cells that drive chronic degenerative diseases and conditions associated with biological aging processes. These include immunology and inflammation (I&I), dermatology and skin aging, metabolic syndrome (obesity, diabetes, liver fibrosis), sarcopenia, and neurodegenerative disease.
Article content
GPX4 is a major antioxidant-regulating enzyme that protects cells and tissues from free radical damage and is essential for cell survival. In contrast, GPX4 deficiency is associated with regulated cell death (RCD), especially ferroptosis. In certain pathologic cells, aging is associated with an imbalance in GPX4. By modulating GPX4 to selectively encourage cell death in ferroptosis-sensitive senescent zombie cells, RLS-1496 may be able to clear these cells to not only fight disease, but also support healthy cells to function properly.
Article content
About Rubedo Life Sciences
Article content
Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate – RLS-1496, a potential first-in-class disease-altering GPX4 modulator – is currently in Phase I clinical trials. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Sunnyvale, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
A surprising study revealed biological activity on a distant planet. Weeks later, scientists say there's more to the story
An artist's concept shows what K2-18b might look like. Thought to be covered entirely in liquid water with a hydrogen-rich atmosphere, the exoplanet may be a good place to look for biological activity. A tiny sign revealed in April seemed like it might change the universe as we know it. Astronomers had detected just a hint, a glimmer of two molecules swirling in the atmosphere of a distant planet called K2-18b — molecules that on Earth are produced only by living things. It was a tantalizing prospect: the most promising evidence yet of an extraterrestrial biosignature, or traces of life linked to biological activity. But only weeks later, new findings suggest the search must continue. 'It was exciting, but it immediately raised several red flags because that claim of a potential biosignature would be historic, but also the significance or the strength of the statistical evidence seemed to be too high for the data,' said Dr. Luis Welbanks, a postdoctoral research scholar at Arizona State University's School of Earth and Space Exploration. While the molecules identified on K2-18b by the April study — dimethyl sulfide, or DMS, and dimethyl disulfide, or DMDS — are associated largely with microbial organisms on our planet, scientists point out that the compounds can also form without the presence of life. Now, three teams of astronomers not involved with the research, including Welbanks, have assessed the models and data used in the original biosignature discovery and got very different results, which they have submitted for peer review. Meanwhile, the lead author of the April study, Nikku Madhusudhan, and his colleagues have conducted additional research that they say reinforces their previous finding about the planet. And it's likely that additional observations and research from multiple groups of scientists are on the horizon. The succession of research papers revolving around K2-18b offers a glimpse of the scientific process unfolding in real time. It's a window into the complexities and nuances of how researchers search for evidence of life beyond Earth — and shows why the burden of proof is so high and difficult to reach. Noisy data Located 124 light-years from Earth, K2-18b is generally considered a worthy target to scour for signs of life. It is thought to be a Hycean world, a planet entirely covered in liquid water with a hydrogen-rich atmosphere, according to previous research led by Madhusudhan, a professor of astrophysics and exoplanetary science at the University of Cambridge's Institute of Astronomy. And as such, K2-18b has rapidly attracted attention as a potentially habitable place beyond our solar system. Convinced of K2-18b's promise, Madhusudhan and his Cambridge colleagues used observations of the planet by the largest space telescope in operation, the James Webb Space Telescope, to study the planet further. But two scientists at the University of Chicago — Dr. Rafael Luque, a postdoctoral scholar in the university's department of astronomy and astrophysics, and Michael Zhang, a 51 Pegasi b / Burbidge postdoctoral fellow — spotted some problems with what they found. After reviewing Madhusudhan and his team's April paper, which followed up on their 2023 research, Luque and Zhang noticed that the Webb data looked 'noisy,' Luque said. Noise, caused by imperfections in the telescope and the rate at which different particles of light reach the telescope, is just one challenge astronomers face when they study distant exoplanets. Noise can distort observations and introduce uncertainties into the data, Zhang said. Trying to detect specific gases in distant exoplanet atmospheres introduces even more uncertainty. The most noticeable features from a gas like dimethyl sulfide stem from a bond of hydrogen and carbon molecules — a connection that can stretch and bend and absorb light at different wavelengths, making it hard to definitively detect one kind of molecule, Zhang said. 'The problem is basically every organic molecule has a carbon-hydrogen bond,' Zhang said. 'There's hundreds of millions of those molecules, and so these features are not unique. If you have perfect data, you can probably distinguish between different molecules. But if you don't have perfect data, a lot of molecules, especially organic molecules, look very similar, especially in the near-infrared.'
CTV News
4 hours ago
- CTV News
Elon Musk pulls back on threat to withdraw Dragon spacecraft
Tesla and SpaceX CEO Elon Musk speaks at the SATELLITE Conference and Exhibition, March 9, 2020, in Washington. (AP Photo/Susan Walsh) As U.S. President Donald Trump and Elon Musk argued on social media on Thursday, the world's richest man threatened to decommission a space capsule used to take astronauts and supplies to the International Space Station. A few hours later, Musk said he wouldn't follow through on the threat. After Trump threatened to cut government contracts given to Musk's SpaceX rocket company and his Starlink internet satellite services, Musk responded via X that SpaceX 'will begin decommissioning its Dragon spacecraft immediately.' It was unclear how serious Musk's threat was, but several hours later -- in a reply to another X user -- he said he wouldn't do it. The capsule, developed with the help of government contracts, is an important part of keeping the space station running. NASA also relies heavily on SpaceX for other programs including launching science missions and, later this decade, returning astronauts to the surface of the moon. The Dragon capsule SpaceX is the only U.S. company capable right now of transporting crews to and from the space station, using its four-person Dragon capsules. Boeing's Starliner capsule has flown astronauts only once; last year's test flight went so badly that the two NASA astronauts had to hitch a ride back to Earth via SpaceX in March, more than nine months after launching last June. Starliner remains grounded as NASA decides whether to go with another test flight with cargo, rather than a crew. SpaceX also uses a Dragon capsule for its own privately run missions. The next one of those is due to fly next week on a trip chartered by Axiom Space, a Houston company. Cargo versions of the Dragon capsule are also used to ferry food and other supplies to the orbiting lab. NASA's other option: Russia Russia's Soyuz capsules are the only other means of getting crews to the space station right now. The Soyuz capsules hold three people at a time. For now, each Soyuz launch carries two Russians and one NASA astronaut, and each SpaceX launch has one Russian on board under a barter system. That way, in an emergency requiring a capsule to return, there is always someone from the U.S. and Russia on board. With its first crew launch for NASA in 2020 -- the first orbital flight of a crew by a private company -- SpaceX enabled NASA to reduce its reliance on Russia for crew transport. The Russian flights had been costing the U.S. tens of millions of dollars per seat, for years. NASA has also used Russian spacecraft for cargo, along with U.S. contractor Northrup Grumman. SpaceX's other government launches The company has used its rockets to launch several science missions for NASA as well as military equipment. Last year, SpaceX also won a NASA contract to help bring the space station out of orbit when it is no longer usable. SpaceX's Starship mega rocket is what NASA has picked to get astronauts from lunar orbit to the surface of the moon, at least for the first two landing missions. Starship made its ninth test flight last week from Texas, but tumbled out of control and broke apart. ------ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Globe and Mail
14 hours ago
- Globe and Mail
Takeaways from AP's report on the business interests of Trump's surgeon general pick
PROVIDENCE, R.I. (AP) — President Donald Trump's pick to be U.S. surgeon general has repeatedly said the nation's medical and food systems are corrupted by special interests and people out to make a profit at the expense of Americans' health. Yet as Dr. Casey Means has criticized scientists, medical schools and regulators for taking money from the food and pharmaceutical industries, she has promoted dozens of products in ways that put money in her own pocket. The Associated Press found Means, who has carved out a niche in the wellness industry, set up deals with an array of businesses. In some cases, she promoted companies in which she was an investor or adviser without consistently disclosing the connection, the AP found. Means, 37, has said she recommends products that she has personally vetted and uses herself. Still, experts said her business entanglements raise concerns about conflicting interests for an aspiring surgeon general, a role responsible for giving Americans the best scientific information on how to improve their health. Here are some takeaways from the AP's reporting. Growing an audience, and selling products Means, 37, earned her medical degree from Stanford University, but she dropped out of her residency program in 2018, and her license to practice is inactive. She said she saw firsthand how 'broken and exploitative the healthcare system is" and turned to alternative approaches to address what she has described as widespread metabolic dysfunction driven largely by poor nutrition and an overabundance of ultra-processed foods. She co-founded Levels, a nutrition, sleep and exercise-tracking app that can also give users insights from blood tests and continuous glucose monitors. The company charges $199 per year for an app subscription and an additional $184 per month for glucose monitors. Though scientists debate whether continuous glucose monitors are beneficial for people without diabetes, U.S. Health Secretary Robert F. Kennedy Jr. has promoted their use as a precursor to making certain weight-loss drugs available to patients. With more than 825,000 followers on Instagram and a newsletter that she has said reached 200,000 subscribers, Means has a direct line to an audience interested in health, nutrition and wellness. Many companies, including Amazon, have affiliate marketing programs in which people with substantial social media followings can sign up to receive a percentage of sales or some other benefit when someone clicks through and buys a product using a special individualized link or code shared by the influencer. Means has used such links to promote various products sold on Amazon. Among them are books, including the one she co-wrote, 'Good Energy"; beauty products; cardamom-flavored dental floss; organic jojoba oil; sunglasses; a sleep mask; a silk pillowcase; fitness and sleep trackers; protein powder and supplements. She also has shared links to products sold by other companies that included 'affiliate' or 'partner' coding. The products include an AI-powered sleep system and the prepared food company Daily Harvest, for which she curated a 'metabolic health collection.' On a 'My Faves' page that was taken down from her website shortly after Trump picked her, Means wrote that some links 'are affiliate links and I make a small percentage if you buy something after clicking them.' It's not clear how much money Means has earned from her affiliate marketing, partnerships and other agreements. Daily Harvest did not return messages seeking comment, and Means said she could not comment on the record during the confirmation process. Disclosing conflicts Influencers who endorse products in exchange for something of value are required by the the Federal Trade Commission to disclose it every time. But most consumers still don't realize that a personality recommending a product might make money if people click through and buy, said University of Minnesota professor Christopher Terry. While Means did disclose some relationships like newsletter sponsors, the AP found she wasn't consistent. For example, a 'Clean Personal & Home Care Product Recommendations' guide she links to from her website contains two dozen affiliate or partner links and no disclosure that she could profit from any sales. Means has said she invested in Function Health, which provides subscription-based lab testing for $500 annually. Of the more than a dozen online posts the AP found in which Means mentioned Function Health, more than half did not disclose she had any affiliation with the company. Though the 'About' page on her website discloses the affiliation, that's not enough, experts said. She is required to disclose any material connection she has to a company any time she promotes it. Representatives for Function Health did not return messages seeking comment. While the disclosure requirements are rarely enforced by the FTC, Means should have been informing her readers of any connections regardless of whether she was violating any laws, said Olivier Sylvain, a Fordham Law School professor, previously a senior advisor to the FTC chair. 'What you want in a surgeon general, presumably, is someone who you trust to talk about tobacco, about social media, about caffeinated alcoholic beverages, things that present problems in public health,' Sylvain said, adding, 'Should there be any doubt about claims you make about products?' Potential conflicts pose new ethical questions Past surgeons general have faced questions about their financial entanglements, prompting them to divest from certain stocks or recuse themselves from matters involving their business relationships for a period of time. Means hasn't yet gone through a Senate confirmation hearing and has not yet announced the ethical commitments she will make for the role. Emily Hund, author of 'The Influencer Industry: The Quest for Authenticity on Social Media,' said as influencer marketing becomes more common, it is raising more ethical questions — like what past influencers who enter government should do to avoid the appearance of a conflict. 'This is like a learning moment in the evolution of our democracy,' Hund said. 'Is this a runaway train that we just have to get on and ride, or is this something that we want to go differently?'
